Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

CMT4A and CMT2K Gene Replacement Therapy with AAV9/GDAP1 in Rats

Award Number: R21NS146806
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2026
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

CMT4A and CMT2K Gene Replacement Therapy with AAV9/GDAP1 in Rats - PROJECT SUMMARY/ABSTRACT Charcot–Marie–Tooth (CMT) neuropathies are a genetically and phenotypically heterogeneous group of disorders caused by pathogenic variants in over 100 different genes. Ganglioside-induced differentiation- associated protein 1 (GDAP1) gene mutations cause various forms of CMT including CMT4A and CMT2K. CMT4A is a severe, early onset neuropathy caused by autosomal recessive, loss of function mutations, while CMT2K is a milder, late onset neuropathy caused by autosomal dominant, gain of function mutations in the GDAP1 gene. Despite the clinical burden and the known GDAP1 cause in CMT4A and CMT2K, the potential of gene replacement therapy (GRT) for these patients remains unexplored. We propose to use an AAV9 vector to carry the GDAP1 gene to the spinal cord neurons and Schwann cells of newly characterized Gdap1 KO and KI rat lines and then to characterize the dose-responsive safety and efficacy of the AAV9/GDAP1 vector. Our central hypothesis is that AAV9-mediated GDAP1 GRT during early development will restore proper protein function and, therefore, ameliorate disease phenotypes in the newly characterized Gdap1 KO and KI rat models. We will test this hypothesis by pursuing two specific aims: Aim 1. Determine the safety and efficacy of AAV9/GDAP1 treatment in the Gdap1 KO rat model of CMT4A. Gdap1 KO rats will be dosed IT with the AAV9/GDAP1 vector at 2.5 or 12 months of age to mimic pre- and post-symptomatic intervention, respectively. A subset of rats treated at 2.5 months old will be euthanized at 1 month post injection to serve as the short-term study to evaluate transgene expression and safety of AAV9/GDAP1 (Aim1A). The remaining rats will be kept as the long-term study to evaluate the safety and efficacy of AAV9/GDAP1 (Aim1B). To evaluate safety, we will closely monitor all treated rats for signs of toxicity through comprehensive assessments. To evaluate efficacy, we will focus on longitudinal in-life behavioral and NCV tests, as well as postmortem histopathological changes on peripheral nerves. Aim 2: Determine the safety and efficacy of AAV9/GDAP1 treatment in the Gdap1 KI rat model of CMT2K. A key scientific question remains if our transgene expression can sufficiently outcompete the dominant- negative GDAP1 allele in the Gdap1R120W heterozygous KI CMT2K model to achieve a significant therapeutic rescue. Some studies have demonstrated the success of using GRT to rescue autosomal dominant mutations. Thus, Aim 2 is designed to evaluate this possibility. Our study will be carried out exactly as described in Aim 1 except in the Gdap1R120W KI rats. If these proof-of-concept studies in Aim 1 and 2 demonstrate favorable efficacy and an absence of toxicity, the data generated will serve as pivotal IND-enabling efficacy evidence, as well as supporting safety evidence. We will leverage our extensive experience to design and carry out the remaining IND-enabling studies. If successful, these efforts are designed to ultimately support the translation of this gene therapy approach into a first-in-human clinical trial. This will be of great significance not only to solve the unmet need for both CMT4A and CMT2K, but also providing a general proof-of-concept for other forms of CMT.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $249,000 )
2026	2026	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/13/2026	NEW	$249,000
														Subtotal = $249,000

Grand Total All Awards = $249,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CMT4A and CMT2K Gene Replacement Therapy with AAV9/GDAP1 in Rats

Award Number: R21NS146806

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2026

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer